
Annual report 2024
added 04-18-2026
Grifols, S.A. EBITDA 2011-2026 | GRFS
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Grifols, S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 595 M | 996 M | 1.13 B | 994 M | 1 B | 545 M | 542 M | 474 M | 349 M | 262 M | 92.8 M |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.13 B | 92.8 M | 635 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AstraZeneca PLC
AZN
|
1.06 B | - | - | $ 96.9 B | ||
|
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M | ||
|
Celldex Therapeutics
CLDX
|
-284 M | $ 34.55 | 2.04 % | $ 2.29 B | ||
|
Alterity Therapeutics Limited
ATHE
|
-17.3 M | $ 4.47 | 12.59 % | $ 10.8 B | ||
|
Adverum Biotechnologies
ADVM
|
-136 M | - | - | $ 86.2 M | ||
|
Akouos
AKUS
|
-84.3 M | - | 0.23 % | $ 488 M | ||
|
I-Mab
IMAB
|
13.8 M | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
-46.1 M | - | 4.14 % | $ 49.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | ||
|
Akari Therapeutics, Plc
AKTX
|
-21.6 M | $ 5.8 | 13.28 % | $ 391 B | ||
|
Aligos Therapeutics
ALGS
|
-87.1 M | $ 6.68 | -12.79 % | $ 66 M | ||
|
Allakos
ALLK
|
-190 M | - | - | $ 28.6 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
557 M | $ 309.66 | -3.27 % | $ 40.6 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | ||
|
Applied Molecular Transport
AMTI
|
-124 M | - | - | $ 10.1 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
172 M | $ 22.88 | 4.91 % | $ 1.07 B | ||
|
Applied Therapeutics
APLT
|
-64.5 M | - | - | $ 8.42 M | ||
|
BioNTech SE
BNTX
|
15.3 B | $ 102.92 | 0.78 % | $ 27.2 B | ||
|
Aptinyx
APTX
|
-62.4 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
-70 M | - | -13.39 % | $ 1.45 M | ||
|
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - | ||
|
Advaxis
ADXS
|
-35.9 M | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-9.93 M | $ 3.04 | -1.3 % | $ 5 M | ||
|
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-23.9 M | - | -10.17 % | $ 12.2 K | ||
|
BioXcel Therapeutics
BTAI
|
-50.2 M | $ 1.15 | 7.48 % | $ 14 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
24.8 M | $ 1.41 | 4.07 % | $ 363 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-37.3 M | - | - | $ 7.46 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-16.2 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
-70.5 M | $ 4.32 | 1.41 % | $ 462 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-11.5 M | $ 24.53 | 1.41 % | $ 3.12 B | ||
|
Burford Capital Limited
BUR
|
242 M | $ 4.96 | 6.1 % | $ 792 M | ||
|
AIkido Pharma
AIKI
|
-55.6 M | - | 1.93 % | $ 17.4 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-9.75 M | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
37.3 M | - | -4.8 % | $ 255 M | ||
|
Cabaletta Bio
CABA
|
-171 M | $ 3.44 | -2.27 % | $ 346 M | ||
|
Autolus Therapeutics plc
AUTL
|
-262 M | $ 1.6 | -0.62 % | $ 426 M | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
AVROBIO
AVRO
|
10.8 M | - | 1083.1 % | $ 745 M | ||
|
BeiGene, Ltd.
BGNE
|
589 M | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
-216 M | - | - | $ 546 M | ||
|
Citius Pharmaceuticals
CTXR
|
-42 M | $ 0.86 | 0.39 % | $ 5.79 M | ||
|
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | ||
|
Cidara Therapeutics
CDTX
|
-176 M | - | - | $ 1.41 B | ||
|
CymaBay Therapeutics
CBAY
|
-101 M | - | - | $ 3.45 B |